Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease G Monteleone, MF Neurath, S Ardizzone, A Di Sabatino, MC Fantini, ... New England Journal of Medicine 372 (12), 1104-1113, 2015 | 475 | 2015 |
Azathioprine or methotrexate in the treatment of patients with steroid‐dependent or steroid‐resistant ulcerative colitis: results of an open‐label study on efficacy and … OA Paoluzi, R Pica, A Marcheggiano, P Crispino, F Iacopini, C Iannoni, ... Alimentary pharmacology & therapeutics 16 (10), 1751-1759, 2002 | 166 | 2002 |
Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis. M Boirivant, R Pica, R DeMaria, R Testi, F Pallone, W Strober The Journal of clinical investigation 98 (11), 2616-2622, 1996 | 165 | 1996 |
Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients M Zippi, C Corrado, R Pica, EV Avallone, C Cassieri, D De Nitto, ... World journal of gastroenterology: WJG 20 (46), 17463, 2014 | 144 | 2014 |
2‐Week Triple Therapy for Helicobacter pylori Infection is Better Than 1‐Week in Clinical Practice: a Large Prospective Single‐Center Randomized Study P Paoluzi, F Iacopini, P Crispino, F Nardi, A Bella, M Rivera, P Rossi, ... Helicobacter 11 (6), 562-568, 2006 | 113 | 2006 |
Anti-tissue transglutaminase antibodies in inflammatory bowel disease: new evidence MD Tola, L Sabbatella, MC Anania, A Viscido, R Caprilli, R Pica, ... Clinical Chemistry and Laboratory Medicine (CCLM) 42 (10), 1092-1097, 2004 | 101 | 2004 |
Inter-observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD) M Daperno, M Comberlato, F Bossa, L Biancone, AG Bonanomi, ... Digestive and Liver Disease 46 (11), 969-973, 2014 | 99 | 2014 |
Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1‐year follow‐up study OA Paoluzi, F Iacopini, R Pica, P Crispino, A Marcheggiano, A Consolazio, ... Alimentary pharmacology & therapeutics 21 (9), 1111-1119, 2005 | 93 | 2005 |
Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects MC Di Paolo, OA Paoluzi, R Pica, F Iacopini, P Crispino, M Rivera, ... Digestive and Liver Disease 33 (7), 563-569, 2001 | 91 | 2001 |
Safety of treatments for inflammatory bowel disease: clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) L Biancone, V Annese, S Ardizzone, A Armuzzi, E Calabrese, F Caprioli, ... Digestive and Liver Disease 49 (4), 338-358, 2017 | 57 | 2017 |
Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis R Pica, OA Paoluzi, F Iacopini, A Marcheggiano, P Crispino, M Rivera, ... Inflammatory bowel diseases 10 (6), 731-736, 2004 | 54 | 2004 |
Diffuse febrile dermatosis in a patient with active ulcerative colitis under treatment with steroids and azathioprine: a case of Sweet’s syndrome: case report and review of … OA Paoluzi, P Crispino, A Amantea, R Pica, F Iacopini, A Consolazio, ... Digestive and liver disease 36 (5), 361-366, 2004 | 53 | 2004 |
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study S Vermeire, PL Lakatos, T Ritter, S Hanauer, B Bressler, R Khanna, ... The Lancet Gastroenterology & Hepatology 7 (1), 28-37, 2022 | 52 | 2022 |
Training programs on endoscopic scoring systems for inflammatory bowel disease lead to a significant increase in interobserver agreement among community gastroenterologists M Daperno, M Comberlato, F Bossa, A Armuzzi, L Biancone, ... Journal of Crohn's and Colitis 11 (5), 556-561, 2017 | 49 | 2017 |
Biological therapy for dermatological manifestations of inflammatory bowel disease M Zippi, R Pica, D De Nitto, P Paoluzi World Journal of Clinical Cases: WJCC 1 (2), 74, 2013 | 46* | 2013 |
One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication F Iacopini, P Crispino, OA Paoluzi, A Consolazio, R Pica, M Rivera, ... Digestive and liver disease 37 (8), 571-576, 2005 | 46 | 2005 |
Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial P Paoluzi, G d'Albasio, A Pera, GB Porro, OA Paoluzi, R Pica, M Cottone, ... Digestive and Liver Disease 34 (11), 787-793, 2002 | 41 | 2002 |
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) G Fiorino, F Caprioli, M Daperno, F Mocciaro, M Principi, A Viscido, ... Digestive and Liver Disease 51 (5), 632-639, 2019 | 40 | 2019 |
Regional variations in the use of complementary and alternative medicines (CAM) for inflammatory bowel disease patients in Italy: An IG-IBD study P Bertomoro, S Renna, M Cottone, G Riegler, F Bossa, L Giglio, ... Journal of Crohn's and Colitis 4 (3), 291-300, 2010 | 36 | 2010 |
Role of desmoplasia in recurrence of stage II colorectal cancer within five years after surgery and therapeutic implication P Crispino, G De Toma, A Ciardi, A Bella, M Rivera, G Cavallaro, ... Cancer investigation 26 (4), 419-425, 2008 | 36 | 2008 |